Phase Appropriate GMPs for Cell and Gene Therapy Compliance with Troy Fugate and Melissa Schneider

  Рет қаралды 453

Compliance Insight

Compliance Insight

11 ай бұрын

Join us for an informative discussion with pharmaceutical and medical device experts, Troy Fugate and Melissa Schneider from Compliance Insight, as they delve into the world of cell and gene therapy compliance. With over 60 years of combined experience, Troy and Melissa provide valuable insights on the phase-appropriate implementation of Good Manufacturing Practices (GMPs) in this rapidly growing industry.
Discover key considerations for controlling raw materials, methods, processes, and data integrity. Gain insights into the challenges and successes along the development path including R&D, Pre-clinical studies, Process and Method Validation & more. Explore the DNA of GMP implementation and learn how to create a roadmap for success in this evolving landscape.
==========================
For more, visit us at www.compliance-insight.com
Compliance Insight is a leading FDA regulatory and quality assurance consulting firm that offers a range of services to assist companies in navigating the complexities of FDA regulations. With their in-depth knowledge and expertise, Compliance Insight provides invaluable guidance and support to ensure compliance with FDA requirements.
One of their key services is assisting companies with the 510(k) process. They understand the intricacies involved in preparing and submitting 510(k) applications for medical devices. Compliance Insight helps clients gather the necessary data, conduct thorough reviews, and ensure the application meets all regulatory standards, streamlining the path to FDA clearance.
In addition, Compliance Insight has extensive experience in the emerging field of cell and gene therapies. They offer specialized guidance on navigating the unique regulatory landscape for these innovative therapies, helping clients understand and meet FDA requirements to bring their life-changing treatments to market.
Another area of expertise for Compliance Insight is providing assistance with 483 and Warning Letter response and remediation. In the event of an FDA inspection resulting in observations or deficiencies (captured in Form 483), Compliance Insight supports companies in developing comprehensive and effective responses. Their team works closely with clients to address each observation, develop appropriate corrective actions, and ensure timely and compliant resolution.
Whether it's navigating the 510(k) process, advancing cell and gene therapies, addressing 483 observations, product recalls, or more; Compliance Insight's services encompass comprehensive regulatory support to help companies achieve and maintain FDA compliance, fostering successful product development and market approval.

Пікірлер
21 CFR, Parts 210 and 211
1:12:03
Compliance Insight
Рет қаралды 25 М.
Я нашел кто меня пранкует!
00:51
Аришнев
Рет қаралды 5 МЛН
- А что в креме? - Это кАкАооо! #КондитерДети
00:24
Телеканал ПЯТНИЦА
Рет қаралды 7 МЛН
孩子多的烦恼?#火影忍者 #家庭 #佐助
00:31
火影忍者一家
Рет қаралды 52 МЛН
Clown takes blame for missing candy 🍬🤣 #shorts
00:49
Yoeslan
Рет қаралды 37 МЛН
GMP requirements for cell and gene therapy institutions-20201112 0600-1
1:05:18
Thermo Fisher Scientific
Рет қаралды 8 М.
It’s Not Just the Genome; AI Can Transform Primary Care
51:34
Commonwealth Club World Affairs of California
Рет қаралды 2,4 М.
FDA Inspection: Preparing for Success - Expert Tips and Best Practices
20:11
2023 Industry Update at the Cell & Gene State of the Industry Briefing
24:04
Alliance for Regenerative Medicine
Рет қаралды 4,2 М.
Lunch & Learn: Gene Therapy 101
1:03:24
ASGCT
Рет қаралды 30 М.
A-Cell: Manufacturing of Cell-Based Therapies
1:02:39
Alliance for Regenerative Medicine
Рет қаралды 8 М.
Basics of AAV Gene Therapy
30:01
ASGCT
Рет қаралды 66 М.
Session 1: An Introduction to Biologic GMP Manufacturing Preparing for Early Phase Clinical Trials
1:28:59
Stem Cell Network - Réseau de cellules souches
Рет қаралды 634
Reality Therapy with Dr  Robert Wubbolding
1:18:34
CSI Omega Zeta Chapter
Рет қаралды 1,5 М.
Preclinical Considerations for Cell and Gene Therapy Products, an FDA Perspective
46:52
U.S. Food and Drug Administration
Рет қаралды 17 М.
Я нашел кто меня пранкует!
00:51
Аришнев
Рет қаралды 5 МЛН